Kinea Bio is a patient-focused biotechnology company striving to accelerate the development of next-generation AAV-based gene therapies to treat neuromuscular diseases. Kinea is developing an integrated technology platform designed to address the most critical challenges facing the field of gene therapy, including novel targeting and gene regulation technologies, advanced engineered tissue modeling capabilities, and strategies that will enable delivery of larger, more functional therapeutic cargos that has previously been possible.
